サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1730917

虚血再灌流障害の世界市場レポート 2025年

Ischemia Reperfusion Injury Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
虚血再灌流障害の世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

虚血再灌流障害市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.7％で、22億6,000万米ドルに成長します。今後、予測期間中の成長は、バイオマーカーに基づく診断への需要の増加、臓器保存技術への意識の高まり、心筋梗塞の罹患率の上昇、医薬品研究開発への投資の増加、幹細胞治療への需要の高まりなどの要因によって牽引されると予想されます。予測期間中に予想される主な動向としては、イメージング技術の発展、新規薬理学的薬剤の開発、治療におけるAIと機械学習の統合、臓器モデリングのための3Dプリンティングの採用、遠隔医療へのシフトなどが挙げられます。

心血管疾患の有病率の増加は、虚血再灌流障害市場の今後の成長を促進すると予想されます。心血管疾患は、冠動脈疾患、心不全、脳卒中など、心臓や血管に影響を及ぼす疾患群です。これらの疾患の増加は、主に不健康な生活習慣と人口の高齢化に起因しています。飽和脂肪、砂糖、塩分の多い食事と運動不足が相まって、心血管疾患の主な危険因子である肥満、高血圧、糖尿病の割合が増加しています。虚血再灌流傷害は、酸化ストレス、炎症、細胞死による組織損傷を強めることで心血管系疾患を悪化させ、最終的には心機能を損ない、心不全やその他の合併症のリスクを高める。例えば、オーストラリア保健福祉研究所の報告によると、オーストラリアにおける冠動脈性心疾患による死亡者数は、2021年の1万4,100人から2022年には1万4,900人に増加しました。このように、心血管疾患の有病率の増加が虚血再灌流障害市場の成長に寄与しています。

臓器移植の頻度の増加は、虚血再灌流障害市場の成長をさらに押し上げると予想されます。臓器移植は、機能不全または損傷した臓器を置き換えるために、健康な臓器をドナーからレシピエントに外科的に移植することを含みます。臓器移植の増加は、医療技術の進歩と臓器不全患者の増加に起因しています。手術技術、免疫抑制剤、臓器保存法の改善により、臓器移植の成功率は著しく向上しました。虚血再灌流障害（IRI）は、移植中の高度な保存技術によって管理することができ、虚血による損傷を最小限に抑え、移植臓器の機能と生存率を向上させることができます。例えば、全米臓器分与ネットワーク（UNOS）によると、米国では2022年に4万2,887件の臓器移植が行われ、2021年から3.7％増加しました。その結果、臓器移植の増加が虚血再灌流障害市場の拡大に重要な役割を果たしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の虚血再灌流障害 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の虚血再灌流障害市場：成長率分析
  • 世界の虚血再灌流障害市場の実績：規模と成長、2019年～2024年
  • 世界の虚血再灌流障害市場の予測：規模と成長、2024年～2029年、2034年
  • 世界の虚血再灌流障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の虚血再灌流障害市場：治療タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 薬物療法
  • 非薬物療法
  • 世界の虚血再灌流障害市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 心血管疾患
  • 脳卒中
  • 臓器移植
  • 心臓発作
  • 糖尿病
  • 世界の虚血再灌流障害市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院
  • クリニック
  • 外来サービス
  • 老人ホーム
  • 世界の虚血再灌流障害市場、薬物療法のサブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 抗酸化物質
  • 抗炎症剤
  • カルシウムチャネル遮断薬
  • フリーラジカルスカベンジャー
  • 一酸化窒素供与体
  • ミトコンドリア保護剤
  • 世界の虚血再灌流障害市場、非薬物療法の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 虚血性プレコンディショニング（IPC）
  • 虚血性ポストコンディショニング（IPO）
  • 遠隔虚血コンディショニング（RIC）
  • 低体温療法
  • 機械的介入
  • 遺伝子および幹細胞治療

第7章 地域別・国別分析

  • 世界の虚血再灌流障害市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界の虚血再灌流障害市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 虚血再灌流障害市場：競合情勢
  • 虚血再灌流障害市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Prolong Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
    • BMG LABTECH GmbH Overview, Products and Services, Strategy and Financial Analysis
    • Domainex Ltd Overview, Products and Services, Strategy and Financial Analysis
    • CFM Pharma Holding BV Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Simcere Innovation Inc.
  • Larix Bioscience LLC
  • Faron Pharmaceuticals Oy
  • LUCA Science Inc.
  • Faraday Pharmaceuticals Inc.
  • Athersys Inc.
  • Alloksys Life Sciences B.V.
  • Ischemix Inc.
  • New Horizons Pharma Inc.
  • Oxitope Pharma BV
  • PharmaTher Holdings Ltd
  • Revive Therapeutics Ltd
  • Corline Biomedical AB
  • Angion Biomedica Corp.
  • Radikal Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 虚血再灌流障害市場2029年：新たな機会を提供する国
  • 虚血再灌流障害市場2029年：新たな機会を提供するセグメント
  • 虚血再灌流障害市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34589

Ischemia-reperfusion injury refers to tissue damage that occurs when blood flow is restored to tissues after a period of ischemia (lack of oxygen). The return of circulation can lead to inflammation and oxidative damage. This injury involves complex pathophysiological processes that have both local and systemic effects.

The primary treatment types for ischemia-reperfusion injury include pharmacological and non-pharmacological therapies. Pharmacological treatments involve the use of medications designed to prevent or address the underlying mechanisms, such as oxidative stress, inflammation, and cell death. These therapies are applied in various conditions, including cardiovascular diseases, stroke, organ transplantation, heart attack, and diabetes. The end users of these treatments include hospitals, clinics, ambulatory services, and nursing homes.

The ischemia reperfusion injury market research report is one of a series of new reports from The Business Research Company that provides ischemia reperfusion injury market statistics, including the ischemia reperfusion injury industry global market size, regional shares, competitors with the ischemia reperfusion injury market share, detailed ischemia reperfusion injury market segments, market trends, and opportunities, and any further data you may need to thrive in the ischemia reperfusion injury industry. This ischemia reperfusion injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ischemia reperfusion injury market size has grown strongly in recent years. It will grow from $1.56 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of cardiovascular diseases, a rise in surgical procedures, growing demand for organ transplantation, an expanding aging population, and a higher incidence of stroke.

The ischemia reperfusion injury market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Looking ahead, the growth during the forecast period is expected to be driven by factors such as the increasing demand for biomarker-based diagnostics, greater awareness of organ preservation techniques, a rising incidence of myocardial infarction, higher investments in pharmaceutical research and development, and growing demand for stem cell therapies. Key trends anticipated in the forecast period include advancements in imaging technologies, the development of novel pharmacological agents, the integration of AI and machine learning in treatments, the adoption of 3D printing for organ modeling, and a shift toward telemedicine.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the ischemia-reperfusion injury market in the future. Cardiovascular diseases are a group of conditions that affect the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The rise in these diseases is primarily attributed to unhealthy lifestyle habits and an aging population. Diets high in saturated fats, sugar, and salt, combined with insufficient physical activity, have contributed to rising rates of obesity, hypertension, and diabetes, which are major risk factors for cardiovascular conditions. Ischemia-reperfusion injury exacerbates cardiovascular diseases by intensifying tissue damage through oxidative stress, inflammation, and cell death, ultimately impairing heart function and raising the risk of heart failure and other complications. For example, the Australian Institute of Health and Welfare reported that deaths from coronary heart disease in Australia rose from 14,100 in 2021 to 14,900 in 2022. Thus, the increasing prevalence of cardiovascular diseases is contributing to the growth of the ischemia-reperfusion injury market.

The increasing frequency of organ transplants is expected to further boost the growth of the ischemia-reperfusion injury market. Organ transplantation involves the surgical transfer of a healthy organ from a donor to a recipient to replace a failing or damaged organ. The rise in organ transplants can be attributed to advances in medical technology and the growing number of organ failure patients. Improvements in surgical techniques, immunosuppressive drugs, and organ preservation methods have significantly enhanced the success rates of organ transplants. Ischemia-reperfusion injury (IRI) can be managed through advanced preservation techniques during transplantation, minimizing ischemia-induced damage and improving the function and survival of the transplanted organ. For instance, according to the United Network for Organ Sharing (UNOS), the United States saw 42,887 organ transplants in 2022, a 3.7% increase from 2021. As a result, the rise in organ transplants is playing a key role in the expansion of the ischemia-reperfusion injury market.

Companies in the ischemia-reperfusion injury market are focusing on developing innovative treatments, such as ketamine-based therapies, to prevent tissue damage and inflammation caused by ischemic events. Ketamine-based treatments use ketamine, a dissociative anesthetic, to address various health conditions, primarily in the treatment of mental health disorders such as depression, anxiety, and PTSD, as well as for pain management. For example, in December 2022, PharmaTher Holdings Ltd., a Canadian pharmaceutical company, received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ketamine to prevent ischemia-reperfusion injury during organ transplantation. Ketamine reduces ischemia-reperfusion injury by inhibiting NF-κB, which suppresses the production of inflammatory cytokines such as IL-6 and TNF-a. Additionally, it exhibits anti-inflammatory properties by reducing leukocyte reactivity, helping minimize immune-mediated damage to transplanted organs.

Major players in the ischemia reperfusion injury market are Pfizer Inc., Prolong Pharmaceuticals LLC, BMG LABTECH GmbH, Domainex Ltd, CFM Pharma Holding BV, Simcere Innovation Inc., Larix Bioscience LLC, Faron Pharmaceuticals Oy, LUCA Science Inc., Faraday Pharmaceuticals Inc., Athersys Inc., Alloksys Life Sciences B.V., Ischemix Inc., New Horizons Pharma Inc., Oxitope Pharma BV, PharmaTher Holdings Ltd, Revive Therapeutics Ltd, Corline Biomedical AB, Angion Biomedica Corp., Radikal Therapeutics Inc.

North America was the largest region in the ischemia reperfusion injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ischemia-reperfusion injury report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ischemia-reperfusion injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ischemia-reperfusion injury market consists of revenues earned by entities by providing services such as diagnostic imaging services, surgical interventions, pharmacological treatment services, rehabilitation and physical therapy, research, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ischemia-reperfusion injury market also includes sales of products including pharmaceuticals and therapeutics, medical devices, diagnostic tools and kits, reperfusion equipment, research tools, and reagents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ischemia Reperfusion Injury Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ischemia reperfusion injury market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ischemia reperfusion injury ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ischemia reperfusion injury market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment Type: Pharmacological Therapy; Non-pharmacological Therapy
  • 2) By Application: Cardiovascular Diseases; Stroke; Organ Transplantation; Heart Attack; Diabetes
  • 3) By End Users: Hospitals; Clinics; Ambulatory Services; Nursing Home
  • Subsegments:
  • 1) By Pharmacological Therapy: Antioxidants; Anti-inflammatory Agents; Calcium Channel Blockers; Free Radical Scavengers; Nitric Oxide Donors; Mitochondrial Protective Agents.
  • 2) By Non-Pharmacological Therapy: Ischemic Preconditioning (IPC); Ischemic Postconditioning (IPO); Remote Ischemic Conditioning (RIC); Hypothermia Therapy; Mechanical Interventions; Gene and Stem Cell Therapy.
  • Companies Mentioned: Pfizer Inc.; Prolong Pharmaceuticals LLC; BMG LABTECH GmbH; Domainex Ltd; CFM Pharma Holding BV
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ischemia Reperfusion Injury Market Characteristics

3. Ischemia Reperfusion Injury Market Trends And Strategies

4. Ischemia Reperfusion Injury Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Ischemia Reperfusion Injury Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Ischemia Reperfusion Injury PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Ischemia Reperfusion Injury Market Growth Rate Analysis
  • 5.4. Global Ischemia Reperfusion Injury Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Ischemia Reperfusion Injury Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Ischemia Reperfusion Injury Total Addressable Market (TAM)

6. Ischemia Reperfusion Injury Market Segmentation

  • 6.1. Global Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmacological Therapy
  • Non-pharmacological Therapy
  • 6.2. Global Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cardiovascular Diseases
  • Stroke
  • Organ Transplantation
  • Heart Attack
  • Diabetes
  • 6.3. Global Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Ambulatory Services
  • Nursing Home
  • 6.4. Global Ischemia Reperfusion Injury Market, Sub-Segmentation Of Pharmacological Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antioxidants
  • Anti-inflammatory Agents
  • Calcium Channel Blockers
  • Free Radical Scavengers
  • Nitric Oxide Donors
  • Mitochondrial Protective Agents
  • 6.5. Global Ischemia Reperfusion Injury Market, Sub-Segmentation Of Non-Pharmacological Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ischemic Preconditioning (IPC)
  • Ischemic Postconditioning (IPO)
  • Remote Ischemic Conditioning (RIC)
  • Hypothermia Therapy
  • Mechanical Interventions
  • Gene and Stem Cell Therapy

7. Ischemia Reperfusion Injury Market Regional And Country Analysis

  • 7.1. Global Ischemia Reperfusion Injury Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Ischemia Reperfusion Injury Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ischemia Reperfusion Injury Market

  • 8.1. Asia-Pacific Ischemia Reperfusion Injury Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ischemia Reperfusion Injury Market

  • 9.1. China Ischemia Reperfusion Injury Market Overview
  • 9.2. China Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ischemia Reperfusion Injury Market

  • 10.1. India Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ischemia Reperfusion Injury Market

  • 11.1. Japan Ischemia Reperfusion Injury Market Overview
  • 11.2. Japan Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ischemia Reperfusion Injury Market

  • 12.1. Australia Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ischemia Reperfusion Injury Market

  • 13.1. Indonesia Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ischemia Reperfusion Injury Market

  • 14.1. South Korea Ischemia Reperfusion Injury Market Overview
  • 14.2. South Korea Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ischemia Reperfusion Injury Market

  • 15.1. Western Europe Ischemia Reperfusion Injury Market Overview
  • 15.2. Western Europe Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ischemia Reperfusion Injury Market

  • 16.1. UK Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ischemia Reperfusion Injury Market

  • 17.1. Germany Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ischemia Reperfusion Injury Market

  • 18.1. France Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ischemia Reperfusion Injury Market

  • 19.1. Italy Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ischemia Reperfusion Injury Market

  • 20.1. Spain Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ischemia Reperfusion Injury Market

  • 21.1. Eastern Europe Ischemia Reperfusion Injury Market Overview
  • 21.2. Eastern Europe Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ischemia Reperfusion Injury Market

  • 22.1. Russia Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ischemia Reperfusion Injury Market

  • 23.1. North America Ischemia Reperfusion Injury Market Overview
  • 23.2. North America Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ischemia Reperfusion Injury Market

  • 24.1. USA Ischemia Reperfusion Injury Market Overview
  • 24.2. USA Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ischemia Reperfusion Injury Market

  • 25.1. Canada Ischemia Reperfusion Injury Market Overview
  • 25.2. Canada Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ischemia Reperfusion Injury Market

  • 26.1. South America Ischemia Reperfusion Injury Market Overview
  • 26.2. South America Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ischemia Reperfusion Injury Market

  • 27.1. Brazil Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ischemia Reperfusion Injury Market

  • 28.1. Middle East Ischemia Reperfusion Injury Market Overview
  • 28.2. Middle East Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ischemia Reperfusion Injury Market

  • 29.1. Africa Ischemia Reperfusion Injury Market Overview
  • 29.2. Africa Ischemia Reperfusion Injury Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Ischemia Reperfusion Injury Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Ischemia Reperfusion Injury Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ischemia Reperfusion Injury Market Competitive Landscape And Company Profiles

  • 30.1. Ischemia Reperfusion Injury Market Competitive Landscape
  • 30.2. Ischemia Reperfusion Injury Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Prolong Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. BMG LABTECH GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Domainex Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. CFM Pharma Holding BV Overview, Products and Services, Strategy and Financial Analysis

31. Ischemia Reperfusion Injury Market Other Major And Innovative Companies

  • 31.1. Simcere Innovation Inc.
  • 31.2. Larix Bioscience LLC
  • 31.3. Faron Pharmaceuticals Oy
  • 31.4. LUCA Science Inc.
  • 31.5. Faraday Pharmaceuticals Inc.
  • 31.6. Athersys Inc.
  • 31.7. Alloksys Life Sciences B.V.
  • 31.8. Ischemix Inc.
  • 31.9. New Horizons Pharma Inc.
  • 31.10. Oxitope Pharma BV
  • 31.11. PharmaTher Holdings Ltd
  • 31.12. Revive Therapeutics Ltd
  • 31.13. Corline Biomedical AB
  • 31.14. Angion Biomedica Corp.
  • 31.15. Radikal Therapeutics Inc.

32. Global Ischemia Reperfusion Injury Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ischemia Reperfusion Injury Market

34. Recent Developments In The Ischemia Reperfusion Injury Market

35. Ischemia Reperfusion Injury Market High Potential Countries, Segments and Strategies

  • 35.1 Ischemia Reperfusion Injury Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Ischemia Reperfusion Injury Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Ischemia Reperfusion Injury Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer